Cargando…
Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study
BACKGROUND: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a treatable autoimmune neurologic syndrome that occurs with or without tumor association. However, some severe cases are refractory to systemic immunotherapy. This pilot study aimed to evaluate the utility and safety of intr...
Autores principales: | Yang, Xun-Zhe, Zhu, Hua-Dong, Ren, Hai-Tao, Zhu, Yi-Cheng, Peng, Bin, Cui, Li-Ying, Guan, Hong-Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776845/ https://www.ncbi.nlm.nih.gov/pubmed/29336363 http://dx.doi.org/10.4103/0366-6999.222327 |
Ejemplares similares
-
Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis
por: Liba, Zuzana, et al.
Publicado: (2017) -
Effectiveness of intra-thecal methotrexate in refractory Anti-N-methyl-d-aspartate receptor encephalitis
por: Hommady, Raid, et al.
Publicado: (2023) -
Study of B Cell Repertoire in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis
por: Feng, Jingjing, et al.
Publicado: (2020) -
Potential Effect of Preoperative Immunotherapy on Anesthesia of Patients with Anti-N-methyl-D-aspartate Receptor Encephalitis
por: Gong, Ya-Hong, et al.
Publicado: (2015) -
Safety of long-term intrathecal methotrexate in progressive forms of
MS
por: Stark, James W., et al.
Publicado: (2019)